Loading the section…

NAUT: financial statements from SEC — TradeAlmanac

NAUT

Nautilus Biotechnology, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Research and development	10M	10M	10M	12M	12M	12M
Selling, general and administrative	6M	6M	7M	7M	7M	8M
Operating expenses	16M	15M	17M	19M	19M	21M
Net income	−15M	−14M	−15M	−17M	−16M	−18M
Earnings per share	−0.12	−0.11	−0.12	−0.13	−0.13	−0.14
Earnings per share, diluted	−0.12	−0.11	−0.12	−0.13	−0.13	−0.14
Weighted average shares	127M	126M	126M	126M	125M	125M
Weighted average shares, diluted	127M	126M	126M	126M	125M	125M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	15M	12M	24M	34M	33M	28M	5M	26M
Current assets	99M	106M	134M

Cash flow

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Operating cash flow	−13M	—	—	−14M	—	—
Depreciation and amortisation	334,000	400,000	400,000	465,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator